Polyclonal Antibody News and Research

RSS

SARS-CoV-2 Omicron variant uses endosomal entry pathway and grows in upper respiratory tract cells

Researchers demonstrate that the SARS-CoV-2 Omicron variant grows rapidly in human primary nasal epithelial cultures.

9 Jan 2022

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

A new study found that the Omicron variant contains a number of mutations that decrease neutralizing antibody activity and immune escape.

6 Jan 2022

New tool to help map immune escape with SARS-CoV-2 mutations

A new study discusses a computational program that can be used to substitute for actual experimental evidence of the biologic impact of new mutations.

12 Dec 2021

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

21 Oct 2021

Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine

Researchers from Singapore conducted a study to assess the spike protein-specific humoral and cellular immunity in Ad26.COV2.S vaccinated individuals either primed with Ad26.COV2.S only, or boosted with a homologous or heterologous second dose.

18 Oct 2021

Antibody validation and rapid peptide mapping technology

In this interview, News-Medical speaks to Bin Ma, President of Rapid Novor, about antibody validation and rapid peptide mapping technology.

From Rapid Novor Inc 11 Oct 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

Study defines SARS-CoV-2 antibodies associated with neutralization and effector functions

A new study explores the polyclonal antibody response to SARS-CoV-2 in greater detail.

10 Aug 2021

A World First: sequencing polyclonal antibodies using only proteomics

News-Medical speaks to Bin Ma, President of Rapid Novor, about their latest research that sequenced polyclonal antibodies using only proteomics.

From Rapid Novor Inc 21 Jun 2021

SARS-CoV-2 spike mutations during transmission among humans and to animals

A fascinating new study discusses the 40 mutations that are seen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and their potential effects on viral biology.

3 May 2021

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

23 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the SARS-CoV-2.

5 Apr 2021

Researchers characterize antibody responses to COVID-19 mRNA-based vaccine

A team of scientists from the USA and Canada has recently characterized the antibodies developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in response to an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

10 Mar 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Urinary shedding of spike protein in COVID-19 patients

A team of scientists from the United States has recently revealed that about 25% of people with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop renal complications and that the viral spike protein can be detected in the urine samples of these patients. The study is currently available on the medRxiv* preprint server.

1 Feb 2021

Moderna vaccine fully neutralizes new SARS-CoV-2 variants, study shows

Researchers in the United States have conducted a study showing that Moderna’s mRNA-1273 vaccine neutralizes all circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tested to date.

26 Jan 2021